BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms

Issued claims relate to methods of treating cerebral aneurysm patients with BA-1049 and other ROCK2 inhibitors and combinations as potential treatment

BOSTON--()--BioAxone BioSciences, Inc., a biotechnology company applying an innovative understanding of axon regeneration and neuronal signaling to transform the lives of patients afflicted with neurotrauma or neurovascular disorders, today announced that it has received an additional Notice of Allowance from the United States Patent and Trademark Office (USPTO). The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.

The new claim expands a previously-issued claim regarding the proprietary method of treatment of cavernous angioma. Both vascular disorders are typified by a disruption in ROCK signaling equilibrium within the blood vessel wall that leads to reduced vascular integrity. Aneurysms are outpockets in the vascular wall susceptible to rupture. Angiomas are abnormal clusters of blood vessels that form leaky vascular lesions in the brain. For both cavernous angioma and cerebral aneurysm, there are no current treatments available other than surgical intervention.

“ROCK2 is implicated in the pathogenesis of cerebral aneurysms and cavernous angiomas. Currently the only option patients have is brain surgery. We are excited to further extend our scientific leadership in ROCK2 inhibition and the treatment of these serious neurovascular disorders,” said Lisa McKerracher, PhD, CEO, BioAxone BioSciences.

BA-1049 is a first-in-class oral inhibitor of Rho Kinase 2 (ROCK2) that has shown a promising safety profile and efficacy in multiple preclinical models of neurovascular disease. A recently published preclinical study established clear proof-of-concept for BA-1049 as a potentially transformative therapy to repair the thin-walled, leaky capillaries that predispose cavernous angioma patients to a lifetime risk of seizure, hemorrhagic stroke and other neurological defects. BioAxone is currently seeking a development partner to lead the clinical development of BA-1049.

About BioAxone BioSciences, Inc.

Based in Boston, BioAxone BioSciences is applying its deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders. Leveraging 20 years of pioneering research in axon regeneration and diseases involving Rho/ROCK signaling, BioAxone has a clinical stage drug (BA-210) and a preclinical program (BA-434) targeting axon regeneration for treatment of spinal cord injury. BA-1049, intended for license, is the lead orally-available ROCK2 inhibitor to restore endothelial cell barrier function in cavernous angioma (CA) and cerebral aneurysms. Cavernous angioma, which has both spontaneous and genetic forms, and cerebral aneurysms, are considered unmet medical needs with no pharmacological treatment options currently available for patients. For more information, visit www.bioaxonebio.com.

Contacts

Beth Kurth
Conway Communications
617-584-9650

Release Summary

Latest NOA covers proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates in development.

Contacts

Beth Kurth
Conway Communications
617-584-9650